Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eprenetapopt + Azacitidine in TP53-Mutant MDS
NCT03745716Phase 3Completed
- Sponsor
- Aprea Therapeutics
- Start
- Jan 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of eprenetapopt in myelodysplastic syndrome (MDS) (2 arms), sponsored by Aprea Therapeutics. Primary endpoint: Complete Response Rate at 12 months. Started Jan 2019; status: completed.
02
Drugs
eprenetapopt
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03745716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745716.